# OnCo record xm22-03 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/xm22-03/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "xm22-03" ;
  schema:name "XM22-03"@en ;
  schema:alternateName "XM22 03"@en, "EudraCT 2009-015999-10"@en ;
  schema:description "XM22-03 showed that lipegfilgrastim, a once-per-cycle injection that boosts white blood cells, kept the spell of dangerously low white cells after chemotherapy as short as the standard booster pegfilgrastim did in people with breast cancer; it was one of the two main studies behind the EU approval of Lonquex."@en ;
  schema:url <https://onco.cc/trials/xm22-03/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1186/1471-2407-13-386>, <https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:drugs <https://onco.cc/drugs/lipegfilgrastim/>, <https://onco.cc/drugs/pegfilgrastim/> ;
  onco:companies <https://onco.cc/companies/teva/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/> .